| Literature DB >> 26136187 |
John P Sasso1, Neil D Eves2, Jesper F Christensen3, Graeme J Koelwyn4, Jessica Scott5, Lee W Jones1.
Abstract
The field of exercise-oncology has increased dramatically over the past two decades, with close to 100 published studies investigating the efficacy of structured exercise training interventions in patients with cancer. Of interest, despite considerable differences in study population and primary study end point, the vast majority of studies have tested the efficacy of an exercise prescription that adhered to traditional guidelines consisting of either supervised or home-based endurance (aerobic) training or endurance training combined with resistance training, prescribed at a moderate intensity (50-75% of a predetermined physiological parameter, typically age-predicted heart rate maximum or reserve), for two to three sessions per week, for 10 to 60 min per exercise session, for 12 to 15 weeks. The use of generic exercise prescriptions may, however, be masking the full therapeutic potential of exercise treatment in the oncology setting. Against this background, this opinion paper provides an overview of the fundamental tenets of human exercise physiology known as the principles of training, with specific application of these principles in the design and conduct of clinical trials in exercise-oncology research. We contend that the application of these guidelines will ensure continued progress in the field while optimizing the safety and efficacy of exercise treatment following a cancer diagnosis.Entities:
Year: 2015 PMID: 26136187 PMCID: PMC4458077 DOI: 10.1002/jcsm.12042
Source DB: PubMed Journal: J Cachexia Sarcopenia Muscle ISSN: 2190-5991 Impact factor: 12.910
Figure 1The principles of training.
Figure 2Oxygen consumption and ventilatory responses to incremental treadmill exercise in a 65 year-old woman with early-stage breast cancer. (A) Increasing workloads during the cardiopulmonary exercise test causes linear increases in oxygen consumption (VO2 in mL/kg/min) to the point of volitional fatigue at a VO2peak of 18.9 mL/kg/min. (B) A graphical representation of alveolar ventilation (VE in L/min) demonstrate two exponential ‘breakpoints’ in ventilation corresponding to Ventilatory Threshold 1 (VT1) and Ventilatory Threshold 2 (VT2). These thresholds demarcate the transition of low, medium, and high exercise intensity, and correspond to specific parameters that may be used for identification of relative intensity for exercise prescription and monitoring. These intensities and the corresponding ranges of physiological identification thereof (heart rate, blood pressure, and rating (Rtg) of perceived exertion on a 6–20 scale) provide an appropriate tool for indirect assessment of training stress and intensity.
Figure 3Comparison of linear and nonlinear exercise prescriptions. Each bar represents a training session at prescribed workloads based on the absolute or relative intensity. (A) The conventional (linear) approach utilizes standard intensity, frequency, and duration parameters after an initial lead in period, with static increases in session duration (i.e. 20 to 45 min). (B) The alternative non-linear approach considers the principles of exercise training in order to optimize the adaptations to the exercise stimulus. Sessions are tailored to an individual's relative intensity, based on cardiopulmonary exercise testing or exercise tolerance testing, and specified to address a particular endpoint. Sessions and weeks progress over the course of the prescription and vary between low intensity (e.g. 55% VO2peak; white bars) and moderate (e.g. 75%; grey bars) and high intensity (e.g. 100% VO2peak; black bars) training in order to target various physiological systems involved in the cardiopulmonary response to exercise. Session intensity is inversely related to session duration, that is, sessions involving high relative intensity workloads are conducted in shorter bouts through short duration training sessions and are less frequent to ensure recovery between sessions. VO2peak, peak rate of oxygen consumption.
Exercise training studies adopting a non-linear approach in exercise-oncology research (chronological order)
| Authors | Population/setting/design/N | Non-linear aerobic exercise training intervention | Major findings |
|---|---|---|---|
| Jones | Operable lung cancer/pre-operative/prospective single-group/25 | Duration: 4–6 weeks | Adverse events: Abnormal decline in systolic blood pressure >20 mmHg, which normalized after exercise determination ( |
| Frequency: five times a week | |||
| Modality: cycle ergometry | Adherence: 72% (number of sessions attended divided by the total number of sessions prescribed) | ||
| Week 1: five sessions: 20 min at 60%; VO2peak up to 30 min at 65% VO2peak | |||
| Weeks 2–3: four sessions: 25–30 min at 60–65% VO2peak; one session: 20–25 min at VT | Outcomes: ITT: VO2peak increased 2.4 mL/kg/min ( | ||
| Week 4+ | |||
| Jones | Non-small cell lung cancer (Stage I–IIIb)/post-surgical /prospective single-group/20 | Duration: 14 weeks | Adverse events: none |
| Frequency: three times a week | |||
| Modality: cycle ergometry | |||
| Week 1: three sessions: 15–20 min at 60% Wmax | Adherence: 85% (number of sessions attended divided by the total number of sessions prescribed) | ||
| Weeks 2–4: three sessions: increased progressively to 30 min at 65% Wmax | |||
| Week 5–6: two sessions: 30–45 min at 60–65% Wmax; one session: 20–25 min at VT | Outcomes: ITT: VO2peak increased 1.1 mL/kg/min ( | ||
| Week 7–10: two sessions: 30–45 min at 60–70% Wmax; one session: 20–30 min at VT | |||
| Week 10–14: two sessions: 30–45 min at 60–70% Wmax; one session: 10–15 times (30 s at VO2peak, followed by 60 s of active recovery) | |||
| Courneya | Mild-to-moderately anaemic patients with solid tumours/during or post-cancer therapy/single-centre, two-armed randomized controlled trial comparing darbepoetin alfa (an erythropoiesis-stimulating agent) alone vs. darbepoetin alfa plus aerobic training/55 | Duration: 12 weeks | Adverse events: none |
| Frequency: three times a week | Adherence: 85% (number of sessions attended divided by the total number of sessions prescribed) | ||
| Modality: cycle ergometry | Outcomes: VO2peak was significantly greater in the exercise group (+3.0 mL/kg/min; | ||
| Intensity: 60–100% of baseline Wmax | |||
| Courneya | Lymphoma/during chemotherapy or following treatment / single-centre, two-armed randomized control trial comparing usual care vs. usual care plus aerobic exercise training/122 | Duration: 12 weeks | Adverse events: none |
| Frequency: three times a week | |||
| Modality: cycle ergometry | |||
| Week 1–4 | Adherence: 78% (duration and intensity criteria were met during 99.0% and 90.7% of sessions) | ||
| Week 5–7: three sessions: 15–20 min at 75% Wmax, increasing 5 min per week to 25–30 min by Week 9 | |||
| Week 7–8: two sessions: 30–35 min at 75% Wmax, increasing 5 min to 35–40 min in Week 8; one session: exercise at VT (time N/R) | Outcomes: Aerobic training was superior to usual care on all indicators of cardiovascular fitness, including VO2peak (+5.2 mL/kg/min), Wmax, (+28 W) and VT (+0.33 L/min) ( | ||
| Week 9–12: two sessions: 30–35 min at 75% Wmax, increasing 5 min per week to 40–45 min by Week 9 to Week 12; one session: interval training at VO2peak (time N/R) | |||
| Hornsby | Operable breast cancer (stage IIb–IIIc)/receiving neo-adjuvant chemotherapy/single-centre, two-armed randomized control trial comparing neoadjuvant AC alone vs. AC plus aerobic exercise training/20 | Duration: 12 weeks | Adverse events: During baseline exercise testing: exercise-induced oxygen desaturation (SpO2 < 84%) ( |
| Frequency: three times a week | |||
| Modality: cycle ergometry | |||
| Week 1: three sessions: 15–20 min at 60% Wmax | Attendance: 82% (number of sessions attended divided by the total number of sessions prescribed) | ||
| Weeks 2–4: three sessions: increased progressively to 30 min at 65% Wmax | |||
| Week 5–6: two sessions: 30–45 min at 60–65% Wmax; one session: 20–25 min at VT | Adherence: 66% (number of sessions successfully completed divided by the number of planned sessions attended. Non-adherence was defined as any exercise session requiring exercise dose modification of either the planned exercise duration or intensity. | ||
| Week 7–10: two sessions: 30–45 min at 60–70% Wmax; one session: 20–30 min at VT | Outcomes: ITT: VO2peak increased by 2.6 mL/kg/min (+13.3%) in the aerobic training group and decreased by 1.5 mL/kg/min (−8.6%) in the AC alone group (mean difference +4.1 mL/kg/min, | ||
| Week 10–12: two sessions: 30–45 min at 60–70% Wmax; one session: 10–15 times (30 s at 100% Wmax, followed by 60 s of active recovery) | |||
| Jones | Localized (stage I–II) prostate adenocarcinoma/post bilateral nerve sparing radical prostatectomy / single-centre, two-armed randomized control trial comparing usual care alone vs. usual care plus aerobic exercise training / 50 | Duration: 6 months | Adverse Events: Ischemic ECG changes reflected by significant ST segment depression were observed in three patients during baseline CPET. 129 independent non-serious adverse events occurred that required modification or early cessation of the exercise training prescription. The majority of events were training-induced leg cramps (55%) or back pain (26%). |
| Frequency: five times a week (minimum three supervised, then two supervised or home setting) | Attendance (supervised): 83% (number of sessions attended divided by the total number of sessions prescribed) | ||
| Modality: treadmill walking | Compliance (supervised): 79% (number of sessions successfully completed divided by the number of planned sessions attended. Non- adherence was defined as any exercise session requiring exercise dose modification of either the planned exercise duration or intensity. | ||
| Duration and intensity: non-linear prescription aimed to meet 30–45 min/session at 55–100% of VO2peak. Intensity based on treadmill speed/grade corresponding %VO2peak elicited during the pre-randomization or mid-point CPET. | Outcomes: VO2peak increased 1.9 mL/kg/min ( |
ITT, intention to treat analysis; PPA, per protocol analysis; Wmax, maximal work rate; VO2peak, peak oxygen consumption; AC, doxorubicin plus cyclophosphamide; CPET, cardiopulmonary exercise test; VT, ventilatory threshold; MWD, minute walk distance.
VT determined by a systematic increase in the VE/VO2 ratio, whereas VE/VCO2 remained constant.